Browsing by Yonsei Author : Paik, Soon Myung

Name:
Paik, Soon Myung [백순명] http://orcid.org/0000-0001-9688-6480
Department :
College of Medicine (의과대학) - BioMedical Science Institute (의생명과학부)
Scopus ID :
(34977365100)

Keyword Cloud

Researcher Network

Showing results 1 to 45 of 45

This table browses all dspace content
Issue DateTitleJournal Title
2020Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck BRITISH JOURNAL OF CANCER
2020Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer SCIENTIFIC REPORTS
2020Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer EXPERIMENTAL AND MOLECULAR MEDICINE
2020Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer BMC CANCER
2020Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapyINTERNATIONAL JOURNAL OF CANCER
2019Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast CancerJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2019A therapeutic strategy for chemotherapy-resistant gastric cancer via destabilization of both β-catenin and ras CANCERS
2019Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY
2018Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancerBritish Journal of Cancer
2018Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsPLoS One
2018Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab Pharmacogenetics and Genomics
201821-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology Breast Cancer Research and Treatment
2018Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerNEW ENGLAND JOURNAL OF MEDICINE
2018Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)BRITISH JOURNAL OF CANCER
2018Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotationLUNG CANCER
2018Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth GENOME RESEARCH
2018Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells with Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRTGASTROENTEROLOGY
2018Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity informationANNALS OF ONCOLOGY
2018AIRVF: a filtering toolbox for precise variant calling in Ion Torrent sequencingBIOINFORMATICS
2017Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial JAMA ONCOLOGY
2017Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchADVANCES IN ANATOMIC PATHOLOGY
2017The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40ANNALS OF SURGICAL ONCOLOGY
201721-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine TherapyJNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2017Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer ONCOTARGET
2017Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinomaANNALS OF ONCOLOGY
2017Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype ONCOTARGET
2017Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancerBREAST CANCER RESEARCH AND TREATMENT
2016Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial JAMA ONCOLOGY
2016EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines MOLECULAR CANCER THERAPEUTICS
2016Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative ONCOTARGET
2016Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy ONCOGENESIS
2016CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer NEW ENGLAND JOURNAL OF MEDICINE
2015Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma ONCOTARGET
2015Prospective Validation of a 21-Gene Expression Assay in Breast Cancer NEW ENGLAND JOURNAL OF MEDICINE
2015Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma MOLECULAR CANCER THERAPEUTICS
2015Prognostic Tests for Estrogen Receptor-Positive Breast Cancer: Need for Global Consideration and Further EvolutionJAMA ONCOLOGY
2015Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialLANCET ONCOLOGY
2015A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2BREAST CANCER RESEARCH AND TREATMENT
2015Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialJOURNAL OF CLINICAL ONCOLOGY
2015Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine YONSEI MEDICAL JOURNAL
2015Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neckCLINICAL CANCER RESEARCH
2015Nanomaterials for theranostics: Recent advances and future challengesCHEMICAL REVIEWS
2014Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.LANCET
2013Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer: Findings from NSABP C-08JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
2013Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
1

Browse

Links